Robert A. Burger

1994–2025 年に発表

72: 論文数
19,834: 被引用数
52: h 指数
70: i10 指数

被引用数

引用元

国・地域

0%27.5%その他 24.6%

機関

分野

トピック

全論文

並び替え

検索で開く

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
著者: Robert A. Burger, Mark F. Brady, Michael A. Bookman, Gini F. Fleming, Bradley J. Monk, Helen Huang, Robert S. Mannel, Howard D. Homesley, Jeffrey M. Fowler, Benjamin E. Greer, Matthew Boente, Michael J. Birrer, Sharon X. Liang - New England Journal of Medicine 2011 被引用: 2,384
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)
著者: Krishnansu S. Tewari, Michael W. Sill, Richard T. Penson, Helen Huang, Lois M. Ramondetta, Lisa M. Landrum, Ana Oaknin, Thomas Reid, Mario M. Leitão, Helen E. Michael, Philip J. DiSaia, Larry J. Copeland, William T. Creasman, Frederick B. Stehman, Mark F. Brady, Robert A. Burger, J.T. Thigpen, Michael J. Birrer, Steven Waggoner, David H. Moore, Katherine Y. Look, Wui-Jin Koh, Bradley J. Monk - The Lancet 2017 被引用: 679
Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study
著者: Dmitriy Zamarin, Robert A. Burger, Michael W. Sill, Daniel J. Powell, Heather A. Lankes, Michael D. Feldman, Oliver Zivanovic, Camille C. Gunderson, Emily Ko, Cara Mathews, Sudarshan Sharma, Andrea R. Hagemann, Samir N. Khleif, Carol Aghajanian - Journal of Clinical Oncology 2020 被引用: 351
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer
著者: Krishnansu S. Tewari, Robert A. Burger, Danielle Enserro, Barbara M. Norquist, Elizabeth M. Swisher, Mark F. Brady, Michael A. Bookman, Gini F. Fleming, Helen Huang, Howard D. Homesley, Jeffrey M. Fowler, Benjamin E. Greer, Matthew Boente, Sharon X. Liang, Chenglin Ye, Carlos Bais, Leslie M. Randall, John K. Chan, J. Stuart Ferriss, Robert L. Coleman, Carol Aghajanian, Thomas J. Herzog, Philip J. DiSaia, Larry J. Copeland, Robert S. Mannel, Michael J. Birrer, Bradley J. Monk - Journal of Clinical Oncology 2019 被引用: 483
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
著者: Deborah K. Armstrong, Brian N. Bundy, Lari Wenzel, Helen Huang, Rebecca N. Baergen, Shashikant Lele, Larry J. Copeland, Joan L. Walker, Robert A. Burger - New England Journal of Medicine 2006 被引用: 2,625
Inherited Mutations in Women With Ovarian Carcinoma
著者: Barbara M. Norquist, Maria I. Harrell, Mark F. Brady, Tom Walsh, Ming K. Lee, Süleyman Gülsüner, Sarah S. Bernards, Silvia Casadei, Yi Qian, Robert A. Burger, John K. Chan, Susan A. Davidson, Robert S. Mannel, Paul DiSilvestro, Heather A. Lankes, Nilsa C. Ramirez, Mary‐Claire King, Elizabeth M. Swisher, Michael J. Birrer - JAMA Oncology 2015 被引用: 764
Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study
著者: Robert F. Ozols, Brian N. Bundy, Benjamin E. Greer, Jeffrey M. Fowler, Daniel L. Clarke‐Pearson, Robert A. Burger, Robert S. Mannel, Koen DeGeest, Ellen M. Hartenbach, Rebecca N. Baergen - Journal of Clinical Oncology 2003 被引用: 2,055
Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer
著者: Payal D. Shah, Stephanie L. Wethington, Cheyenne Pagan, Nawar Latif, János L. Tanyi, Lainie P. Martin, Mark A. Morgan, Robert A. Burger, Ashley Haggerty, Haley Zarrin, Diego Rodriguez, Susan M. Domchek, Ronny Drapkin, Ie−Ming Shih, Simon A. Smith, Emma Dean, Stéphanie Gaillard, Deborah K. Armstrong, Drew A. Torigian, Wei‐Ting Hwang, Robert Giuntoli, Fiona Simpkins - Gynecologic Oncology 2021 被引用: 117
American Society of Clinical Oncology Position Statement on Obesity and Cancer
著者: Jennifer A. Ligibel, Catherine M. Alfano, Kerry S. Courneya, Wendy Demark‐Wahnefried, Robert A. Burger, Rowan T. Chlebowski, Carol J. Fabian, Ayca Gucalp, Dawn L. Hershman, Melissa M. Hudson, Lee W. Jones, Madhuri Kakarala, Kirsten K. Ness, Janette K. Merrill, Dana S. Wollins, Clifford A. Hudis - Journal of Clinical Oncology 2014 被引用: 524
A phase 1b dose escalation study of ipafricept (OMP 54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer
著者: Kathleen N. Moore, Camille C. Gunderson, Paul Sabbatini, D. Scott McMeekin, Gina Mantia-Smaldone, Robert A. Burger, Mark A. Morgan, Ann M. Kapoun, Rainer K. Brachmann, Robert Stagg, Azeez Farooki, Roisin E. O’Cearbhaill - Gynecologic Oncology 2019 被引用: 104
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study
著者: Benoît You, Christopher Purdy, Larry J. Copeland, Elizabeth M. Swisher, Michael A. Bookman, Gini F. Fleming, Robert L. Coleman, Leslie M. Randall, Krishnansu S. Tewari, Bradley J. Monk, Robert S. Mannel, Joan L. Walker, Fabio Cappuccini, David E. Cohn, Mahvish Muzaffar, David G. Mutch, Andrea E. Wahner Hendrickson, Lainie P. Martin, Olivier Colomban, Robert A. Burger - Journal of Clinical Oncology 2022 被引用: 75
Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study
著者: Barbara M. Norquist, Mark F. Brady, Maria I. Harrell, Tom Walsh, Ming K. Lee, Süleyman Gülsüner, Sarah S. Bernards, Silvia Casadei, Robert A. Burger, Krishnansu S. Tewari, Floor Backes, Robert S. Mannel, Gretchen Glaser, Cheryl L. Bailey, Stephen C. Rubin, John T. Soper, Heather A. Lankes, Nilsa C. Ramirez, Mary‐Claire King, Michael J. Birrer, Elizabeth M. Swisher - Clinical Cancer Research 2017 被引用: 235
Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial
著者: Robert L. Coleman, Katelyn F. Handley, Robert A. Burger, Graziela Zibetti Dal Molin, Robert Stagg, Anil K. Sood, Kathleen N. Moore - Gynecologic Oncology 2020 被引用: 42
Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup
著者: Michael A. Bookman, Mark F. Brady, William P. McGuire, Peter Harper, David S. Alberts, Michael Friedländer, Nicoletta Colombo, Jeffrey M. Fowler, Peter A. Argenta, Koen De Geest, David G. Mutch, Robert A. Burger, Ann Marie Swart, Edward L. Trimble, Chrisann Accario-Winslow, Lawrence M. Roth - Journal of Clinical Oncology 2009 被引用: 707
Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses
著者: Carlos Bais, Barbara M. Mueller, Mark F. Brady, Robert S. Mannel, Robert A. Burger, Wei Wei, Koen M. Marien, Mark Kockx, Amreen Husain, Michael J. Birrer, NRG Oncology/Gynecologic Oncology Group - JNCI Journal of the National Cancer Institute 2017 被引用: 108
Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study
著者: Robert A. Burger, Michael W. Sill, Bradley J. Monk, Benjamin E. Greer, Joel I. Sorosky - Journal of Clinical Oncology 2007 被引用: 880
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
著者: Ignace Vergote, Giovanni Scambia, David M. O’Malley, Ben Van Calster, Sang‐Yoon Park, Josep M. del Campo, Werner Meier, Aristotelis Bamias, Nicoletta Colombo, Robert M. Wenham, Al Covens, Christian Marth, Mansoor Raza Mirza, Judith R. Kroep, Haijun Ma, Cheryl A. Pickett, Bradley J. Monk, Ignace Vergote, Giovanni Scambia, Sangyoon Park, Yong Sang Song, Yulia Makarova, Joshua Trinidad, Hys Ngan, Aristotelis Bamias, Gerasimos Aravantinos, Joo‐Hyun Nam, Vera Gorbunova, Л. И. Крикунова, Duk‐Soo Bae, Jóse Ángel Arranz Arija, Mansoor Raza Mirza, Claudio Zamagni, Christos N. Papandreou, Francesco Raspagliesi, Alla Lisyanskaya, Ana Oaknin Benzaquen, Germana Tognon, Eugenia Ortega, Antonio Casado Herraez, Joseph Buscema, Andrew Green, Robert A. Burger, Dina Sakaeva, Andres Redondo Sanchez, Sharad Ghamande, Laurel A. King, Edgar Petru, Ulla Peen, Satoshi Takeuchi, Kimio Ushijima, Antonio González-Martı́n, Scott Kamelle, Michael E. Carney, Christian Marth, Frédéric Forget, J. Bentley, Jalid Sehouli, Nicoletta Colombo, Paolo Zola, Hidenori Kato, Natalya Fadeeva, Evgeny Gotovkin, Vladimir Vladimirov, Margarita Romeo Marin, Eva Guerra Alía, Mark S. Shahin, Snehalkumar M Bhoola, Krishnansu S. Tewari, Daniel M. Anderson, Brigitte Honhon, J. Pelgrims, Amit M. Oza, Jesús García-Donás Jiménez, Vincent Hansen, David M. O’Malley, Ivor Benjamin, Vincent Renard, Heidi Van den Bulck, Werner Meier, Claudia Haenle, G. Koumakis, Harushige Yokota, В.М. Попов, William E. Bradley, Robert M. Wenham, Robert H. Reid, Donna McNamara, Richard D. Friedman, Joyce N. Barlin, Nicola M. Spirtos, Julia Chapman, P. Sevelda, Manon Huizing, C. Lamot, Frédéric Goffin, Lionel D. Hondt, Allan Covens, Silvana Spadafora, Beate Rautenberg ほか 237 名 - The Lancet Oncology 2019 被引用: 86
Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer
著者: Stephen A. Cannistra, Ursula A. Matulonis, Richard T. Penson, Julie Hambleton, Jakob Dupont, Howard Mackey, Jeffrey A. Douglas, Robert A. Burger, Deborah K. Armstrong, Robert M. Wenham, William P. McGuire - Journal of Clinical Oncology 2007 被引用: 756
PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer
著者: R. Wendel Naumann, Robert L. Coleman, Robert A. Burger, Edward A. Sausville, E. Kutarska, Sharad Ghamande, Nashat Gabrail, Stephen DePasquale, Elżbieta Nowara, Lucy Gilbert, Robert H. Gersh, Michael Teneriello, Wael A. Harb, Panagiotis A. Konstantinopoulos, Richard T. Penson, James T. Symanowski, C. Lovejoy, Christopher P. Leamon, David Morgenstern, Richard A. Messmann - Journal of Clinical Oncology 2013 被引用: 233
An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience
著者: Kate Oliver, William E. Brady, Michael J. Birrer, David M. Gershenson, Gini F. Fleming, Larry J. Copeland, Krishnansu S. Tewari, Peter A. Argenta, Robert S. Mannel, Angeles Alvarez Secord, Jean-Marie Stephan, David G. Mutch, Frederick B. Stehman, Franco M. Muggia, Peter G. Rose, Deborah K. Armstrong, Michael A. Bookman, Robert A. Burger, John Farley - Gynecologic Oncology 2017 被引用: 99
Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218
著者: Angeles Alvarez Secord, Kirsten B. Burdett, Kouros Owzar, David Tritchler, Alexander B. Sibley, Yingmiao Liu, Mark D. Starr, John C. Brady, Heather A. Lankes, Herbert I. Hurwitz, Robert S. Mannel, Krishnansu S. Tewari, David M. O’Malley, Heidi J. Gray, Jamie N. Bakkum‐Gamez, Keiichi Fujiwara, Matthew Boente, Wei Deng, Robert A. Burger, Michael J. Birrer, Andrew B. Nixon - Clinical Cancer Research 2020 被引用: 57
Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study
著者: Krishnansu S. Tewari, James Java, Ramez N. Eskander, Bradley J. Monk, Robert A. Burger - Annals of Oncology 2015 被引用: 133
BRCA Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer
著者: Ying L. Liu, Pier Selenica, Qin Zhou, Alexia Iasonos, Margaret K. Callahan, Noah Z. Feit, Julia L. Boland, Ignacio Vázquez-Garćıa, Diana Mandelker, Ahmet Zehir, Robert A. Burger, Daniel J. Powell, Claire F. Friedman, Karen A. Cadoo, Rachel N. Grisham, Jason Konner, Roisin E. O’Cearbhaill, Carol Aghajanian, Jorge S. Reis‐Filho, Britta Weigelt, Dmitriy Zamarin - JCO Precision Oncology 2020 被引用: 50
Phase III Trial of Doxorubicin Plus Cisplatin With or Without Paclitaxel Plus Filgrastim in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study
著者: Gini F. Fleming, Virginia L. Brunetto, David Cella, Katherine Y. Look, Gary C. Reid, Adnan Munkarah, Richard Kline, Robert A. Burger, Annekathryn Goodman, R. Tucker Burks - Journal of Clinical Oncology 2004 被引用: 567